Loading…
Crescent Biopharma, Inc. is projected to rise to $20.31 by 2027, a +17% move from its current price of $17.34. CBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $16.77 | $17.34 | $17.92 | -0.01% |
| Jul 14 | $16.54 | $17.34 | $18.17 | -0.01% |
| Jul 15 | $16.37 | $17.34 | $18.36 | -0.02% |
| Jul 16 | $16.22 | $17.34 | $18.52 | -0.02% |
| Jul 17 | $16.10 | $17.33 | $18.67 | -0.03% |
| Jul 18 | $15.98 | $17.33 | $18.80 | -0.03% |
| Jul 19 | $15.88 | $17.33 | $18.92 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.88 | $17.33 | $18.92 | -0.04% |
| Week 2 | $15.31 | $17.33 | $19.61 | -0.08% |
| Week 3 | $14.88 | $17.32 | $20.16 | -0.12% |
| Week 4 | $14.53 | $17.31 | $20.63 | -0.16% |
| Week 5 | $14.22 | $17.30 | $21.05 | -0.20% |
| Week 6 | $13.96 | $17.30 | $21.44 | -0.24% |
| Week 7 | $13.71 | $17.29 | $21.80 | -0.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Crescent Biopharma, Inc. is a biotechnology company in the Healthcare sector that researches and develops cancer therapy candidates in the United States.
Its pipeline includes CR-001, which is in Phase 3, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; CR-002 and CR-003.
The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. It was formerly GlycoMimetics, Inc.; the company was founded in 2024 and is headquartered in Waltham, Massachusetts.
CBIO trades for $17.09 per share and has a market capitalization of $471.25M.
It is ranked 3105 by market cap.
The near-term price path is informed by a bullish technical backdrop, while the longer horizon forecasts show rising averages through 2030, 2040 and 2050, with 2030 average at $32.37 and 2050 average at $158.37.
Max values along the path include $50.68 (2030), $90.10 (2035), $123.15 (2040), and $333.78 (2050).
A major floor 40.3% below — a decisive break under it would weaken the trend.
The nearest floor, 3.3% below — buyers have tended to step in here.
The nearest ceiling, 23.8% above — a clean break opens room to run.
A major ceiling 55.6% above — clearing it would confirm fresh momentum.
Key CBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.98 | Buy | $17.09 | Buy |
| MA 10 | $17.36 | Sell | $17.23 | Buy |
| MA 20 | $17.57 | Sell | $17.56 | Sell |
| MA 50 | $18.51 | Sell | $17.93 | Sell |
| MA 100 | $17.01 | Buy | $17.14 | Buy |
| MA 200 | $14.60 | Buy | $17.30 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.41 | Neutral |
| Stoch RSI (14) | 52.28 | Neutral |
| CCI (20) | -31.90 | Neutral |
| Williams %R (14) | -67.78 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -0.91 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 32.22 | Neutral |
| TRIX (15) | -0.38 | Sell |
| Awesome (5,34) | -1.24 | Sell |
| Ultimate (7,14,28) | 37.83 | Neutral |
| Momentum (10) | 0.35 | Buy |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 16.81 | Buy |
| ADX (14) | 11.96 | Neutral |
| ATR (14) | 0.46 | Info |
The 30-day technical picture is bullish.
RSI14 is 40, with a 50-day simple moving average at $19.34 and a 200-day simple moving average at $14.50.
Current price sits near support at $16.99, with resistance at $21.47; the 30-day range spans $13.34 to $21.89. The annualized volatility is 70%, indicating substantial price swings.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.94 | $17.34 | $21.47 | 0% | Neutral | |
| $15.84 | $20.31 | $27.72 | +17% | Neutral | |
| $17.39 | $23.07 | $32.89 | +33% | Bullish | |
| $21.97 | $30.01 | $44.25 | +73% | Bullish | |
| $23.84 | $33.40 | $50.67 | +93% | Bullish | |
| $24.05 | $34.49 | $53.64 | +99% | Bullish | |
| $26.13 | $38.31 | $60.90 | +121% | Bullish | |
| $25.04 | $37.48 | $60.78 | +116% | Bullish | |
| $26.88 | $41.03 | $67.77 | +137% | Bullish | |
| $34.60 | $53.84 | $90.43 | +210% | Bullish | |
| $41.89 | $71.13 | $128.20 | +310% | Bullish | |
| $85.09 | $168.65 | $336.51 | +873% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.94 | $17.34 | $20.35 | +0.00% |
| August 2026 | $14.16 | $16.81 | $20.57 | -3.05% |
| September 2026 | $14.40 | $17.25 | $21.39 | +2.60% |
| October 2026 | $14.07 | $16.97 | $21.28 | -1.62% |
| November 2026 | $13.50 | $16.38 | $20.73 | -3.46% |
| December 2026 | $13.78 | $16.82 | $21.47 | +2.67% |
Click any year to see its month-by-month CBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Crescent Biopharma, Inc.'s 2026 outlook centres on $17.34, within a $8.94 to $21.47 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CBIO could reach as high as $27.72, with a base case around $20.31 and support toward $15.84 — roughly +17% from $17.34. A consolidation phase looks the most probable path here.
Expect CBIO to range from $17.39 to $32.89 through 2028. The $23.07 average target implies a +33% move from current prices. That is up +14% on the projected 2027 average. Momentum favours further upside here.
The CBIO price prediction for 2029 points to an average of $30.01 (low $21.97, high $44.25) — a potential gain of +73% on today's $17.34. Buyers look set to stay in control over this stretch.
In 2030, CBIO is projected to trade between $23.84 and $50.67, averaging $33.40 — a potential gain of +93% from today's $17.34. That is up +11% on the projected 2029 average. Momentum favours further upside here.
Crescent Biopharma, Inc.'s 2031 outlook centres on $34.49, within a $24.05 to $53.64 range. That is up +3% on the projected 2030 average. That marks a +99% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CBIO could reach as high as $60.90, with a base case around $38.31 and support toward $26.13 — roughly +121% from $17.34. Momentum favours further upside here.
Expect CBIO to range from $25.04 to $60.78 through 2033. The $37.48 average target implies a +116% move from current prices. That is -2% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The CBIO price prediction for 2034 points to an average of $41.03 (low $26.88, high $67.77) — a potential gain of +137% on today's $17.34. Momentum favours further upside here.
In 2035, CBIO is projected to trade between $34.60 and $90.43, averaging $53.84 — a potential gain of +210% from today's $17.34. That is up +31% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Crescent Biopharma, Inc.'s 2040 outlook centres on $71.13, within a $41.89 to $128.20 range. That is up +32% on the projected 2035 average. That marks a +310% change versus current levels. Momentum favours further upside here.
By 2050, CBIO could reach as high as $336.51, with a base case around $168.65 and support toward $85.09 — roughly +873% from $17.34. Buyers look set to stay in control over this stretch.
Investing $1,000 in CBIO today (≈ 57.670127 CBIO) could be worth
$9,725.94
+$8,725.94 (+873%) by 2050 · US Dollar
Based on the average projected CBIO price of $168.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CBIOwould be worth at today's price.
$1,000 invested in CBIO on Jul 10, 2025 (≈ 74.074074 CBIO) would be worth
$1,284.44
+$284.44 (+28.4%) today · 1.28× · US Dollar
Based on a CBIO entry price of $13.5 vs. today's $17.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.09 | $1,014.63 | +1.5% |
| 1 month ago | $17.57 | $986.91 | -1.3% |
| 3 months ago | $18.17 | $954.32 | -4.6% |
| 6 months ago | $10.98 | $1,579.24 | +57.9% |
| 1 year ago | $13.5 | $1,284.44 | +28.4% |
| All time (5.0y) ago | $216 | $80.28 | -92.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CBIO forecast.
Our base-case forecast reaches $35.00 around 2032.
Implied market cap at $35.00: $965.02M
The multi-year outlook is bullish across the horizon. The average price is projected to move from $17.09 in 2026 to $19.64 in 2027, $22.03 in 2028, $29.38 in 2029, $32.37 in 2030, $32.87 in 2031, $36.69 in 2032, $34.70 in 2033, $37.92 in 2034 and $51.49 in 2035, before rising to $65.20 in 2040 and $158.37 in 2050.
Projected ROIs rise along the path: 2030 ROI 89.4%; 2031 ROI 92.3%; 2032 ROI 114.7%; 2033 ROI 103%; 2034 ROI 121.9%; 2035 ROI 201.3%; then 2040 ROI 281.5% and 2050 ROI 826.7%.
The longer horizon shows continued upside in the low hundreds of percent by 2050. Risks include high price volatility, with an annualized volatility of 70%, and the uncertainty inherent in long-range forecasts.
Tap a question to reveal the answer.
Avg price $32.37; Min $22.41; Max $50.68; ROI 89.4%; sentiment BULLISH.
Forecasts show rising averages and sizable long-run upside (2030 avg $32.37 to 2050 avg $158.37, ROI up to 826.7%), but near-term ROI is 0% in 2026 and volatility is high (70%).
Yes—the 2035 max is $90.10, which includes the possibility of prices above $70.
Current price $17.09; market cap $471.25M; rank 3105.
Min $15.07; Avg $19.64; Max $27.37; ROI 14.9%; sentiment NEUTRAL.
Crescent Biopharma, Inc. Community Discussion
0Share your Crescent Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.